西藏药业(600211) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥547,772,923.42, representing a decrease of 10.93% compared to the same period last year[8]. - Net profit attributable to shareholders for Q3 2023 was ¥259,437,146.43, an increase of 43.70% year-on-year[8]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥151,344,008.24, down 15.07% from the previous year[8]. - Basic earnings per share for Q3 2023 were ¥1.05, up 43.81% compared to the same period last year[9]. - The company's operating revenue for the first three quarters of 2023 reached ¥787,381,389.01, representing a 21.2% increase from ¥649,413,631.89 in the same period of 2022[27]. - Operating profit for the first three quarters of 2023 was ¥740,963,160.33, up from ¥522,546,471.71 in the previous year, indicating a significant growth[27]. - Net profit for the first three quarters of 2023 was ¥673,914,160.65, compared to ¥478,990,208.33 in 2022, reflecting an increase of 40.7%[27]. - The total profit for the first three quarters of 2023 was ¥740,684,939.85, compared to ¥521,634,346.41 in 2022, marking an increase of 41.9%[27]. - Net profit for the period was ¥863,520,088.44, compared to ¥446,968,616.30 in the previous year, reflecting a significant increase of approximately 93.2%[42]. - The total profit amounted to ¥954,669,621.35, up from ¥512,635,895.59, which is an increase of about 86.1% year-over-year[42]. Cash Flow and Liquidity - The net cash flow from operating activities for Q3 2023 was ¥238,432,419.42, an increase of 89.37% year-on-year[8]. - The net cash flow from operating activities for the first three quarters of 2023 was CNY 783,284,510.25, representing a 30.3% increase compared to CNY 601,097,449.90 in the same period of 2022[20]. - Cash and cash equivalents increased to CNY 1,685,686,872.77, up 47.9% from CNY 1,139,829,573.93 year-over-year[18]. - The net cash flow from operating activities for Q3 2023 was $563,510,846.90, a significant increase from $178,010,298.32 in Q3 2022, representing a growth of approximately 216%[49]. - Cash inflow from investment activities totaled $2,102,301,002.61 in Q3 2023, compared to $959,091,893.85 in Q3 2022, marking an increase of about 119%[49]. - Cash and cash equivalents at the end of Q3 2023 amounted to $379,971,730.53, up from $51,836,589.10 at the end of Q3 2022, indicating a substantial increase[49]. - The company reported a cash outflow from financing activities of $495,641,490.74 in Q3 2023, compared to $131,817,162.07 in Q3 2022, indicating a significant increase in cash outflows[49]. - Cash inflow from financing activities was ¥605,000,000.00, an increase from ¥491,820,520.06, marking a growth of about 23%[62]. - Net cash flow from financing activities dropped to -¥222,425,124.64 from ¥25,325,963.46, indicating a decline of approximately 979%[62]. Assets and Liabilities - Total assets at the end of Q3 2023 were ¥4,721,414,662.75, reflecting a 15.17% increase from the end of the previous year[9]. - As of September 30, 2023, the total current assets amounted to CNY 3,343,904,226.00, an increase of 23.3% from CNY 2,712,113,992.32 on December 31, 2022[18]. - The total assets as of September 30, 2023, reached CNY 4,271,726,590.66, up from CNY 3,885,784,693.22 at the end of 2022, reflecting a growth of 9.9%[25]. - The total liabilities increased to CNY 678,455,818.28, compared to CNY 483,448,918.13 at the end of 2022, marking an increase of 40.5%[26]. - The total equity as of September 30, 2023, was CNY 3,593,270,772.38, an increase from CNY 3,402,335,775.09 at the end of 2022, indicating a growth of 5.6%[26]. - Total liabilities increased to CNY 1,275,153,275.17 from CNY 1,068,641,506.26, reflecting a growth of approximately 19.3%[40]. - The total assets as of Q3 2023 were $3,885,784,693.22, a slight decrease from $3,886,141,827.09 in Q3 2022[55]. - The total liabilities stood at ¥1,026,205,088.37, indicating stable management of financial obligations[72]. Shareholder Information - The company reported a total of 41,601 common shareholders at the end of the reporting period[33]. - The largest shareholder, Tibet Kangzhe Enterprise Management Co., Ltd., holds 32.28% of the shares, totaling 80,033,379 shares[33]. - The company has a total of 41,601 common shareholders, indicating a stable shareholder base[33]. Research and Development - Research and development expenses decreased to ¥8,231,916.12 in 2023 from ¥64,138,506.33 in 2022, showing a reduction of approximately 87.2%[27]. - Research and development expenses decreased to ¥8,319,437.14 from ¥79,908,994.62, showing a reduction of approximately 89.6%[41]. Government Subsidies - The company received increased government subsidies during the reporting period, contributing to the rise in net profit[11]. - The company received government subsidies amounting to ¥116,834,220.31 during the reporting period, slightly down from ¥117,449,348.35 in the previous year[31].